Nishida Haruka, Takehara Kohei, Onodera Takako, Watanabe Saya, Takasaki Kazuki, Takahashi Yuko, Ichinose Takayuki, Hirano Mana, Hiraike Haruko, Nagasaka Kazunori
Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo, 173-8605, Japan.
BMC Womens Health. 2025 Mar 29;25(1):150. doi: 10.1186/s12905-025-03681-8.
Adenomyosis, characterized by endometrial tissue within the uterine muscle, often presents with severe pelvic pain and menorrhagia. This case series demonstrates the efficacy of sequential therapy involving relugolix followed by dienogest in managing adenomyosis.
In five patients with adenomyosis, the gonadotropin-releasing hormone antagonist relugolix initially mitigated symptoms and reduced the levels of serum CA125, a marker associated with disease activity. After six months of relugolix, patients were transitioned to dienogest. This sequential approach maintained symptom relief and further stabilized CA125 levels.
Our findings demonstrate that sequential therapy provides effective symptom management and long-term disease control. Further, CA125 remains a valuable biomarker for monitoring therapeutic success.
子宫腺肌病以子宫肌层内存在子宫内膜组织为特征，常表现为严重的盆腔疼痛和月经过多。本病例系列证明了瑞卢戈利序贯地诺孕素治疗子宫腺肌病的疗效。
在5例子宫腺肌病患者中，促性腺激素释放激素拮抗剂瑞卢戈利最初缓解了症状并降低了血清CA125水平，CA125是一种与疾病活动相关的标志物。使用瑞卢戈利6个月后，患者转为使用地诺孕素。这种序贯治疗方法维持了症状缓解，并进一步稳定了CA125水平。
我们的研究结果表明，序贯治疗可有效管理症状并实现疾病的长期控制。此外，CA125仍然是监测治疗成功的有价值的生物标志物。
